Middle East and Africa Clinical Trial Supplies Market – Industry Trends and Forecast to 2029

Pedido de resumo Pedido de TOC Fale com Analista Fale com o analista  Comprar agora Comprar agora Consulte antes Comprar Consulte antes Relatório de amostra grátis Relatório de amostra grátis

Middle East and Africa Clinical Trial Supplies Market – Industry Trends and Forecast to 2029

  • Healthcare
  • Publish Reports
  • Mar 2022
  • MEA
  • 350 Páginas
  • Número de tabelas: 34
  • Número de figuras: 35

Middle East And Africa Clinical Trial Supplies Market

Tamanho do mercado em biliões de dólares

CAGR :  % Diagram

Diagram Período de previsão
2023 –2029
Diagram Tamanho do mercado (ano base )
US$ MILHÕES
Diagram Tamanho do mercado ( Ano de previsão)
USD 62.01
Diagram CAGR
%
Diagram Principais participantes do mercado
  • Movianto
  • Sharp
  • Thermo Fisher Scientific
  • Catalent
  • PCI Pharma Services

>Mercado de Material para Ensaios Clínicos no Médio Oriente e África, por Serviços (Armazenamento, Fabrico, Embalagem e Rotulagem), Fase Clínica (Fase III, Fase II, Fase IV, Fase I), Usos Terapêuticos (Oncologia, Doenças Cardiovasculares, Dermatologia, Perturbações Metabólicas, Doenças Infecciosas , Doenças Respiratórias, Perturbações do SNC e Mentais, Perturbações do Sangue, Outras), Utilizador Final (Organizações de Investigação Contratadas, Empresas Farmacêuticas e de Biotecnologia), Tendências do Setor e Previsão para 2029.

Middle East and Africa Clinical Trial Supplies Market

Análise de mercado e insights : Mercado de fornecimentos para ensaios clínicos no Médio Oriente e em África

Espera-se que o mercado de fornecimento de ensaios clínicos no Médio Oriente e em África ganhe crescimento de mercado no período de previsão de 2022 a 2029. A Data Bridge Market Research analisa que o mercado está a crescer com um CAGR de 7,0% no período de previsão de 2022 a 2029 e prevê-se que atinja os 62,01 milhões de dólares até 2029. O principal fator que impulsiona o crescimento do mercado de fornecimento de ensaios clínicos é o aumento da procura em ensaios clínicos em todo o mundo, o aumento da incidência de doenças, os fundos governamentais para investimentos em I&D e o desenvolvimento de novos tratamentos, como a medicina personalizada, liderando o ensaio clínico proporciona mercado para crescer no futuro.

O ensaio clínico é um estudo de investigação que determina se uma estratégia, tratamento ou dispositivo médico é seguro, eficaz e útil para uso humano. Estes estudos ajudam a descobrir quais as abordagens médicas melhores para determinadas doenças. Um ensaio clínico fornece os melhores dados para efeitos de tomada de decisão em cuidados de saúde.

O objetivo do ensaio clínico é estudar padrões científicos rigorosos. Estes padrões protegem os doentes e ajudam na produção de resultados de estudos fiáveis.

Os ensaios clínicos são a última etapa do desenvolvimento de medicamentos num longo e cuidadoso processo de investigação realizado por cientistas ou investigadores para uma doença específica, seja um medicamento ou dispositivo médico. O processo de desenvolvimento de medicamentos começa geralmente num laboratório, onde os cientistas desenvolvem e testam primeiro novas ideias relacionadas com o tratamento de doenças.

O relatório do mercado de fornecimentos para ensaios clínicos no Médio Oriente e em África fornece detalhes de quota de mercado, novos desenvolvimentos e análise de pipeline de produtos, impacto dos participantes do mercado doméstico e localizado, analisa as oportunidades em termos de bolsas de receitas emergentes, alterações nas regulamentações de mercado, aprovações de produtos , estratégias decisões, lançamentos de produtos, expansões geográficas e inovações tecnológicas no mercado. Para compreender a análise e o cenário do mercado contacte-nos para um Analyst Brief, a nossa equipa irá ajudá-lo a criar uma solução de impacto na receita para atingir o objetivo desejado.

Métrica de reporte

Detalhes

Período de previsão

2022 a 2029

Ano base

2021

Anos históricos

2020 (personalizável para 2019 - 2014)

Unidades Quantitativas

Receita em milhões de dólares, volumes em unidades, preços em dólares

Segmentos cobertos

Por Serviços (Armazenamento, Fabrico, Acondicionamento e Rotulagem), Fase Clínica (Fase III, Fase II, Fase IV, Fase I), Usos Terapêuticos (Oncologia, Doenças Cardiovasculares, Dermatologia, Perturbações Metabólicas, Doenças Infeciosas, Doenças Respiratórias, SNC e Mentais Perturbações, Perturbações do Sangue, Outros), Utilizador Final (Organizações de Investigação Contratadas, Empresas Farmacêuticas e de Biotecnologia)

Países abrangidos

África do Sul, Resto do Médio Oriente e África (MEA) como parte do Médio Oriente e África (MEA)

Participantes do mercado abrangidos

Movianto (EUA), Sharp (EUA), Thermo Fisher Scientific Inc., (EUA), Catalent, Inc (EUA), PCI Pharma Services (EUA), Almac Group (Reino Unido), PAREXEL International Corporation (EUA), Bionical Ltd .

Dinâmica do mercado de fornecimentos para ensaios clínicos

Motoristas

  • Aumento da procura por ensaios clínicos em todo o mundo

A crescente procura de ensaios clínicos tem sido de 82% só em países em desenvolvimento, como a América do Norte, Global e Ásia. Estes medicamentos estão disponíveis no mercado após o ensaio clínico, pelo que todas as empresas realizam principalmente ensaios clínicos dependendo do tipo de medicamento ou dispositivo e, portanto, atuam como um grande impulsionador que resultará na expansão da taxa de crescimento do mercado de tratamento.

  • Aumento da incidência de doenças crónicas

A elevada prevalência de doenças crónicas devido ao rápido aumento da população e das infecções entre as pessoas pode ser observada em todo o mundo. Estas doenças contribuem com um papel importante no campo dos ensaios clínicos para o desenvolvimento de medicamentos. O medicamento necessita de passar por toda a fase clínica padrão para estar disponível antes do consumo humano. Assim, para tratar estas doenças crónicas em humanos, o medicamento tem de ser seguro.

  • Fundos governamentais em investimentos em I&D

Os instrumentos, a força de trabalho, a gestão médica em caso de danos para os investigadores, o seguro, o transporte, as taxas da comissão de ética, o tratamento de dados e outros consumíveis levam a um grande envolvimento de custos nos ensaios clínicos. Os ensaios clínicos são a avaliação de ideias de prevenção e tratamento de doenças que irão aumentar ainda mais o crescimento do mercado de tratamento.

Oportunidades

  • Aumento dos ensaios de desenvolvimento de novos medicamentos nos países emergentes

O ensaio clínico para a eficácia dos medicamentos é a chave primária para o desenvolvimento de medicamentos para o tratamento de doenças antes do lançamento no mercado para consumo humano. Além disso, os novos medicamentos têm de cumprir extensões de licença e normas internacionais antes de serem vendidos e distribuídos. O aumento da prevalência e da incidência de doenças e o aumento do número de doentes são os factores que conduziram às tendências emergentes de ensaios clínicos para o desenvolvimento de medicamentos nos países em desenvolvimento durante o período passado.

Also, governments in emerging markets (China, Brazil, Russia, India, and South Africa) reform public healthcare and grant more accessible access to medicine. These two factors working in unison mean greater freedom for market developments and increased innovation in clinical research in emerging markets.

Restraints/Challenges

Adverse drug reactions are the unwanted or harmful effects that can be experienced after the administration of a drug under normal conditions of use in humans. The drug reactions generally occur in jaundice, anaemia, rashes and lead to a decrease in the white blood cell count, damaged kidney, and nerve injury that caused impaired vision or hearing.

Many of the adverse effects may be ascertained from physical examinations during the clinical phase of testing. Thus, reporting adverse effects during clinical trial is the major leading restraints factor for the supplies market. Despite high time and cost investments for developing biologics and new drugs, it is estimated that lower procedure time and rate for approval of drug is creating a biggest challenge for the market, which may hamper the market growth.

This clinical trial supplies market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on clinical trial supplies market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

  • In February 2022, Thermo Fisher Scientific has announced partnership with Medidata to optimize clinical research site selection and speed patient enrollment in clinical trial. This improves clinical trial planning and execution to accelerate clinical trial in which datasets have been generated from 26,000 clinical trial and nearly 8 million patients in more than 140 countries across the globe

Middle East and Africa Clinical Trial Supplies Market

Middle East and Africa Clinical Trial Supplies Market Scope

Middle East and Africa clinical trial supplies market is categorized based on services, clinical phase, therapeutic uses and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.

Service

  • Manufacturing
  • Distribution
  • Storage
  • Packaging and Labelling

On the basis of services the Middle East and Africa clinical trial supplies market is segmented into manufacturing, distribution, storage, and packaging and labelling.

Clinical Phase

  • Phase I
  • Phase II
  • Phase III
  • Phase IV

On the basis of clinical phase the Middle East and Africa clinical trial supplies market is segmented into phase I, phase II, phase III and phase IV.

Therapeutic Uses

  • Oncology
  • CNS
  • Mental Disorders
  • Cardiovascular Diseases
  • Infectious Diseases 
  • Respiratory Diseases
  • Blood Disorder
  • Dermatology
  • Others

On the basis of therapeutic uses, the Middle East and Africa clinical trial supplies market is segmented into oncology, CNS and mental disorders, cardiovascular diseases, infectious disease, respiratory diseases, metabolic disorders, blood disorders, dermatology and others.

End User

  • Contract research organizations
  • Pharmaceutical and biotechnology companies

On the basis of end user, the Middle East and Africa clinical trial supplies market is segmented into contract research organizations and pharmaceutical and biotechnology companies.

Clinical Trial Supplies Market Regional Analysis/Insights

Middle East & Africa clinical trial supplies market are further segmented into major countries such as the South Africa, and rest of Middle East and Africa.

South Africa dominates the clinical trial supplies market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period of 2022-2029. This is due to the rising investment in the healthcare sector and growing government support for well-developed healthcare infrastructure for their citizens in this region.

The country section of the report also provides individual market impacting factors and changes in regulations in the market that impact the current and future trends of the market. Data points, such as new and replacement sales, country demographics, and import-export tariffs, are some of the major pointers used to forecast the market scenario for individual countries. In addition, the presence and availability of Middle East and Africa brands and their challenges faced due to high competition from local and domestic brands, and impact of sales channels are considered while providing forecast analysis of the country data.

Competitive Landscape and Middle East and Africa Clinical Trial Supplies Market Share Analysis

Middle East and Africa clinical trial supplies market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trial pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to clinical trial supplies market.

The major prominent participants operating in the Middle East and Africa clinical trial supplies market are Movianto (U.S.), Sharp (U.S.),Thermo Fisher Scientific Inc.,(U.S.), Catalent, Inc (U.S.), PCI Pharma Services (U.S.), Almac Group (U.K.), PAREXEL International Corporation (U.S.), Bionical Ltd. (U.K.), Alium Medical Limited (U.K.), MYODERM (U.K.), Clinigen Group plc (U.K.), Ancillare, LP (U.S.), SIRO Clinpharm (India) CLINICAL SUPPLIES MANAGEMENT HOLDINGS, INC. (U.S.) Biocair (U.K.) and among others.

Research Methodology: Middle East and Africa Clinical Trial Supplies Market

Data collection and base year analysis are done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. In adition, market share analysis and key trend analysis are the major success factors in the market report.. The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, GlobalVsRegional and Vendor Share Analysis. Please request analyst call in case of further inquiry.


SKU-

Obtenha acesso online ao relatório sobre a primeira nuvem de inteligência de mercado do mundo

  • Painel interativo de análise de dados
  • Painel de análise da empresa para oportunidades de elevado potencial de crescimento
  • Acesso de analista de pesquisa para personalização e customização. consultas
  • Análise da concorrência com painel interativo
  • Últimas notícias, atualizações e atualizações Análise de tendências
  • Aproveite o poder da análise de benchmark para um rastreio abrangente da concorrência
Pedido de demonstração

Índice

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF MIDDLE EAST & AFRICA CLINICAL TRIAL SUPPLIES MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 SERVICES LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 VENDOR SHARE ANALYSIS

2.11 SECONDARY SOURCES

2.12 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL ANALYSIS

4.2 PORTERS FIVE FORCES

5 MIDDLE EAST & AFRICA CLINICAL TRIAL SUPPLIES MARKET: REGULATORY SCENARIO

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 RISING DEMAND FOR CLINICAL TRIALS WORLDWIDE

6.1.2 INCREASING INCIDENCE OF CHRONIC DISEASES

6.1.3 GOVERNMENT FUNDS IN R&D INVESTMENTS

6.1.4 ADVANCEMENT OF TECHNOLOGY IN CLINICAL TRIALS SUPPLIES

6.2 RESTRAINTS

6.2.1 ADVERSE EFFECTS OF CLINICAL TRIALS

6.2.2 TRANSPORTATION ISSUE IN CLINICAL TRIAL SUPPLIES

6.2.3 HIGH COST ASSOCIATED WITH THE CLINICAL TRIALS

6.3 OPPORTUNITIES

6.3.1 INCREASING NEW DRUG DEVELOPMENT TRIALS IN EMERGING COUNTRIES

6.3.2 INCREASING DEMAND FOR INNOVATIVE SOLUTIONS IN CLINICAL TRIALS SERVICES

6.3.3 EVOLUTION IN SUPPLY CHAIN MANAGEMENT FOR CLINICAL TRIALS

6.4 CHALLENGES

6.4.1 LOWER PROCEDURE TIME OF CLINICAL TRIALS APPROVAL

6.4.2 LACK OF SKILLED PERSON TO OPERATE DEVICES DURING CLINICAL TRIALS

7 MIDDLE EAST & AFRICA CLINICAL TRIAL SUPPLIES MARKET, BY SERVICES

7.1 OVERVIEW

7.2 STORAGE

7.3 MANUFACTURING

7.4 PACKAGING AND LABELLING

7.5 DISTRIBUTION

8 MIDDLE EAST & AFRICA CLINICAL TRIAL SUPPLIES MARKET, BY CLINICAL PHASES

8.1 OVERVIEW

8.2 PHASE III

8.3 PHASE II

8.4 PHASE IV

8.5 PHASE I

9 MIDDLE EAST & AFRICA CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC USE

9.1 OVERVIEW

9.2 ONCOLOGY

9.3 CARDIOVASCULAR DISEASES

9.4 DERMATOLOGY

9.5 METABOLIC DISORDERS

9.6 INFECTIOUS DISEASES

9.7 RESPIRATORY DISEASES

9.8 CNS AND MENTAL DISORDERS

9.9 BLOOD DISORDERS

9.1 OTHERS

10 MIDDLE EAST & AFRICA CLINICAL TRIAL SUPPLIES MARKET, BY END USER

10.1 OVERVIEW

10.2 CONTRACT RESEARCH ORGANIZATIONS

10.3 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES

11 MIDDLE EAST & AFRICA CLINICAL TRIAL SUPPLIES MARKET, BY REGION

11.1 MIDDLE EAST & AFRICA

11.1.1 SOUTH AFRICA

11.1.2 REST OF MIDDLE EAST & AFRICA

12 MIDDLE EAST & AFRICA CLINICAL TRIAL SUPPLIES MARKET: COMPANY LANDSCAPE

12.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA

13 SWOT ANALYSIS

14 COMPANY PROFILE

14.1 THERMO FISHER SCIENTIFIC INC.

14.1.1 COMPANY SNAPSHOT

14.1.2 REVENUE ANALYSIS

14.1.3 COMPANY SHARE ANALYSIS

14.1.4 PRODUCT PORTFOLIO

14.1.5 RECENT DEVELOPMENT

14.1.5.1 PARTNERSHIP

14.2 ALMAC GROUP

14.2.1 COMPANY SNAPSHOT

14.2.2 COMPANY SHARE ANALYSIS

14.2.3 PRODUCT PORTFOLIO

14.2.4 RECENT DEVELOPMENTS

14.3 CATALENT INC.

14.3.1 COMPANY SNAPSHOT

14.3.2 REVENUE ANALYSIS

14.3.3 COMPANY SHARE ANALYSIS

14.3.4 SERVICE PORTFOLIO

14.3.5 RECENT DEVELOPMENT

14.3.5.1 SERVICE EXPANSION

14.4 CLINIGEN GROUP PLC

14.4.1 COMPANY SNAPSHOT

14.4.2 REVENUE ANALYSIS

14.4.3 COMPANY SHARE ANALYSIS

14.4.4 PRODUCT PORTFOLIO

14.4.5 RECENT DEVELOPMENT

14.4.5.1 PARTNERSHIP

14.5 MOVIANTO

14.5.1 COMPANY SNAPSHOT

14.5.2 COMPANY SHARE ANALYSIS

14.5.3 SERVICE PORTFOLIO

14.5.4 RECENT DEVELOPMENT

14.5.4.1 ACQUISITION

14.6 PCI PHARMA SERVICES

14.6.1 COMPANY SNAPSHOT

14.6.2 SERVICE PORTFOLIO

14.6.3 RECENT DEVELOPMENTS

14.7 SHARP

14.7.1 COMPANY SNAPSHOT

14.7.2 SERVICE PORTFOLIO

14.7.3 RECENT DEVELOPMENT

14.8 ALIUM MEDICAL LIMITED

14.8.1 COMPANY SNAPSHOT

14.8.2 SERVICE PORTFOLIO

14.8.3 RECENT DEVELOPMENT

14.9 ANCILLARE, LP

14.9.1 COMPANY SNAPSHOT

14.9.2 SERVICE PORTFOLIO

14.9.3 RECENT DEVELOPMENT

14.1 BIOCAIR

14.10.1 COMPANY SNAPSHOT

14.10.2 SERVICE PORTFOLIO

14.10.3 RECENT DEVELOPMENTS

14.11 BIONICAL LTD.

14.11.1 COMPANY SNAPSHOT

14.11.2 SERVICE PORTFOLIO

14.11.3 RECENT DEVELOPMENT

14.11.3.1 SERVICE LAUNCH

14.12 CLINICAL SUPPLIES MANAGEMENT HOLDINGS,INC

14.12.1 COMPANY SNAPSHOT

14.12.2 SERVICE PORTFOLIO

14.12.3 RECENT DEVELOPMENT

14.13 KLIFO

14.13.1 COMPANY SNAPSHOT

14.13.2 SERVICE PORTFOLIO

14.13.3 RECENT DEVELOPMENTS

14.13.3.1 ACQUISTION

14.14 MYONEX

14.14.1 COMPANY SNAPSHOT

14.14.2 SERVICE PORTFOLIO

14.14.3 RECENT DEVELOPMENT

14.15 PAREXEL INTERNATIONAL CORPORATION

14.15.1 COMPANY SNAPSHOT

14.15.2 SERVICE PORTFOLIO

14.15.3 RECENT DEVELOPMENT

14.15.3.1 COLLABORATION

14.16 SIRO CLINPHARM PRIVATE LIMITED

14.16.1 COMPANY SNAPSHOT

14.16.2 SERVICE PORTFOLIO

14.16.3 RECENT DEVELOPMENTS

15 QUESTIONNAIRE

16 RELATED REPORTS

Lista de Tabela

TABLE 1 LOCATIONS OF REGISTERED STUDIES

TABLE 2 MIDDLE EAST & AFRICA CLINICAL TRIAL SUPPLIES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 3 MIDDLE EAST & AFRICA STORAGE IN CLINICAL TRIAL SUPPLIES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 4 MIDDLE EAST & AFRICA MANUFACTURING IN CLINICAL TRIAL SUPPLIES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 5 MIDDLE EAST & AFRICA PACKAGING AND LABELLING IN CLINICAL TRIAL SUPPLIES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 6 MIDDLE EAST & AFRICA DISTRIBUTION IN CLINICAL TRIAL SUPPLIES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 7 MIDDLE EAST & AFRICA CLINICAL TRIAL SUPPLIES MARKET, BY CLINICAL PHASE, 2020-2029 (USD MILLION)

TABLE 8 MIDDLE EAST & AFRICA PHASE III IN CLINICAL TRIAL SUPPLIES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 9 MIDDLE EAST & AFRICA PHASE II IN CLINICAL TRIAL SUPPLIES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 10 MIDDLE EAST & AFRICA PHASE IV IN CLINICAL TRIAL SUPPLIES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 11 MIDDLE EAST & AFRICA PHASE I IN CLINICAL TRIAL SUPPLIES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 12 MIDDLE EAST & AFRICA CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC USE, 2020-2029 (USD MILLION)

TABLE 13 MIDDLE EAST & AFRICA ONCOLOGY IN CLINICAL TRIAL SUPPLIES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 14 MIDDLE EAST & AFRICA CARDIOVASCULAR DISEASES IN CLINICAL TRIAL SUPPLIES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 15 MIDDLE EAST & AFRICA DERMATOLOGY IN CLINICAL TRIAL SUPPLIES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 16 MIDDLE EAST & AFRICA METABOLIC DISORDERS IN CLINICAL TRIAL SUPPLIES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 17 MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN CLINICAL TRIAL SUPPLIES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 18 MIDDLE EAST & AFRICA RESPIRATORY DISEASES IN CLINICAL TRIAL SUPPLIES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 19 MIDDLE EAST & AFRICA CNS AND MENTAL DISORDERS IN CLINICAL TRIAL SUPPLIES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 20 MIDDLE EAST & AFRICA BLOOD DISORDERS IN CLINICAL TRIAL SUPPLIES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 21 MIDDLE EAST & AFRICA OTHERS IN CLINICAL TRIAL SUPPLIES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 22 MIDDLE EAST & AFRICA CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 23 MIDDLE EAST & AFRICA CONTRACT RESEARCH ORGANIZATIONS IN CLINICAL TRIAL SUPPLIES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 24 MIDDLE EAST & AFRICA PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN CLINICAL TRIAL SUPPLIES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 25 MIDDLE EAST & AFRICA CLINICAL TRIAL SUPPLIES MARKET, BY COUNTRY, 2020-2029 (USD MILLION)

TABLE 26 MIDDLE EAST & AFRICA CLINICAL TRIAL SUPPLIES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 27 MIDDLE EAST & AFRICA CLINICAL TRIAL SUPPLIES MARKET, BY CLINICAL PHASE, 2020-2029 (USD MILLION)

TABLE 28 MIDDLE EAST & AFRICA CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC USE, 2020-2029 (USD MILLION)

TABLE 29 MIDDLE EAST & AFRICA CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 30 SOUTH AFRICA CLINICAL TRIAL SUPPLIES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 31 SOUTH AFRICA CLINICAL TRIAL SUPPLIES MARKET, BY CLINICAL PHASE, 2020-2029 (USD MILLION)

TABLE 32 SOUTH AFRICA CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC USE, 2020-2029 (USD MILLION)

TABLE 33 SOUTH AFRICA CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 34 REST OF MIDDLE EAST & AFRICA CLINICAL TRIAL SUPPLIES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

Lista de Figura

FIGURE 1 MIDDLE EAST & AFRICA CLINICAL TRIAL SUPLLIES MARKET: SEGMENTATION

FIGURE 2 MIDDLE EAST & AFRICA CLINICAL TRIAL SUPPLIES MARKET: DATA TRIANGULATION

FIGURE 3 MIDDLE EAST & AFRICA CLINICAL TRIAL SUPPLIES MARKET: DROC ANALYSIS

FIGURE 4 MIDDLE EAST & AFRICA CLINICAL TRIAL SUPPLIES MARKET: MIDDLE EAST & AFRICA VS REGIONAL MARKET ANALYSIS

FIGURE 5 MIDDLE EAST & AFRICA CLINICAL TRIAL SUPPLIES MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 MIDDLE EAST & AFRICA CLINICAL TRIAL SUPLLIES MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 MIDDLE EAST & AFRICA CLINICAL TRIAL SUPPLIES MARKET: DBMR MARKET POSITION GRID

FIGURE 8 MIDDLE EAST & AFRICA CLINICAL TRIAL SUPPLIES MARKET: DBMR VENDOR SHARE ANALYSIS

FIGURE 9 MIDDLE EAST & AFRICA CLINICAL TRIAL SUPPLIES MARKET: SEGMENTATION

FIGURE 10 NORTH AMERICA IS EXPECTED TO DOMINATE THE MIDDLE EAST & AFRICA CLINICAL TRIAL SUPPLIES MARKET IN THE FORECAST PERIOD OF 2022 TO 2029

FIGURE 11 RISING DEMAND FOR CLINICAL TRIALS WORLDWIDE AND INCREASING INCIDENCES OF DISEASES IS DRIVING THE MIDDLE EAST & AFRICA CLINICAL TRIAL SUPPLIES MARKET IN THE FORECAST PERIOD OF 2022 TO 2029

FIGURE 12 STORAGE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST & AFRICA CLINICAL TRIAL SUPPLIES MARKET IN 2022 & 2029

FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF MIDDLE EAST & AFRICA CLINICAL TRIAL SUPPLIES MARKET

FIGURE 14 MIDDLE EAST & AFRICA CLINICAL TRIAL SUPPLIES MARKET: BY SERVICES, 2021

FIGURE 15 MIDDLE EAST & AFRICA CLINICAL TRIAL SUPPLIES MARKET: BY SERVICES, 2022-2029 (USD MILLION)

FIGURE 16 MIDDLE EAST & AFRICA CLINICAL TRIAL SUPPLIES MARKET: BY SERVICES, CAGR (2022-2029)

FIGURE 17 MIDDLE EAST & AFRICA CLINICAL TRIAL SUPPLIES MARKET: BY SERVICES, LIFELINE CURVE

FIGURE 18 MIDDLE EAST & AFRICA CLINICAL TRIAL SUPPLIES MARKET: BY CLINICAL PHASE, 2021

FIGURE 19 MIDDLE EAST & AFRICA CLINICAL TRIAL SUPPLIES MARKET: BY CLINICAL PHASE, 2022-2029 (USD MILLION)

FIGURE 20 MIDDLE EAST & AFRICA CLINICAL TRIAL SUPPLIES MARKET: BY CLINICAL PHASE, CAGR (2022-2029)

FIGURE 21 MIDDLE EAST & AFRICA CLINICAL TRIAL SUPPLIES MARKET: BY CLINICAL PHASE, LIFELINE CURVE

FIGURE 22 MIDDLE EAST & AFRICA CLINICAL TRIAL SUPPLIES MARKET: BY THERAPEUTIC USE, 2021

FIGURE 23 MIDDLE EAST & AFRICA CLINICAL TRIAL SUPPLIES MARKET: BY THERAPEUTIC USE, 2022-2029 (USD MILLION)

FIGURE 24 MIDDLE EAST & AFRICA CLINICAL TRIAL SUPPLIES MARKET: BY THERAPEUTIC USE, CAGR (2022-2029)

FIGURE 25 MIDDLE EAST & AFRICA CLINICAL TRIAL SUPPLIES MARKET: BY THERAPEUTIC USE, LIFELINE CURVE

FIGURE 26 MIDDLE EAST & AFRICA CLINICAL TRIAL SUPPLIES MARKET: BY END USER, 2021

FIGURE 27 MIDDLE EAST & AFRICA CLINICAL TRIAL SUPPLIES MARKET: BY END USER, 2022-2029 (USD MILLION)

FIGURE 28 MIDDLE EAST & AFRICA CLINICAL TRIAL SUPPLIES MARKET: BY END USER, CAGR (2022-2029)

FIGURE 29 MIDDLE EAST & AFRICA CLINICAL TRIAL SUPPLIES MARKET: BY END USER, LIFELINE CURVE

FIGURE 30 MIDDLE EAST & AFRICA CLINICAL TRIAL SUPPLIES MARKET: SNAPSHOT (2021)

FIGURE 31 MIDDLE EAST & AFRICA CLINICAL TRIAL SUPPLIES MARKET: BY COUNTRY (2021)

FIGURE 32 MIDDLE EAST & AFRICA CLINICAL TRIAL SUPPLIES MARKET: BY COUNTRY (2022 & 2029)

FIGURE 33 MIDDLE EAST & AFRICA CLINICAL TRIAL SUPPLIES MARKET: BY COUNTRY (2021 & 2029)

FIGURE 34 MIDDLE EAST & AFRICA CLINICAL TRIAL SUPPLIES MARKET: BY SERVICES (2022-2029)

FIGURE 35 MIDDLE EAST & AFRICA CLINICAL TRIAL SUPPLIES MARKET: COMPANY SHARE 2021 (%)

View Detailed Information Right Arrow

Metodologia de Investigação

A recolha de dados e a análise do ano base são feitas através de módulos de recolha de dados com amostras grandes. A etapa inclui a obtenção de informações de mercado ou dados relacionados através de diversas fontes e estratégias. Inclui examinar e planear antecipadamente todos os dados adquiridos no passado. Da mesma forma, envolve o exame de inconsistências de informação observadas em diferentes fontes de informação. Os dados de mercado são analisados ​​e estimados utilizando modelos estatísticos e coerentes de mercado. Além disso, a análise da quota de mercado e a análise das principais tendências são os principais fatores de sucesso no relatório de mercado. Para saber mais, solicite uma chamada de analista ou abra a sua consulta.

A principal metodologia de investigação utilizada pela equipa de investigação do DBMR é a triangulação de dados que envolve a mineração de dados, a análise do impacto das variáveis ​​de dados no mercado e a validação primária (especialista do setor). Os modelos de dados incluem grelha de posicionamento de fornecedores, análise da linha de tempo do mercado, visão geral e guia de mercado, grelha de posicionamento da empresa, análise de patentes, análise de preços, análise da quota de mercado da empresa, normas de medição, análise global versus regional e de participação dos fornecedores. Para saber mais sobre a metodologia de investigação, faça uma consulta para falar com os nossos especialistas do setor.

Personalização disponível

A Data Bridge Market Research é líder em investigação formativa avançada. Orgulhamo-nos de servir os nossos clientes novos e existentes com dados e análises que correspondem e atendem aos seus objetivos. O relatório pode ser personalizado para incluir análise de tendências de preços de marcas-alvo, compreensão do mercado para países adicionais (solicite a lista de países), dados de resultados de ensaios clínicos, revisão de literatura, mercado remodelado e análise de base de produtos . A análise de mercado dos concorrentes-alvo pode ser analisada desde análises baseadas em tecnologia até estratégias de carteira de mercado. Podemos adicionar quantos concorrentes necessitar de dados no formato e estilo de dados que procura. A nossa equipa de analistas também pode fornecer dados em tabelas dinâmicas de ficheiros Excel em bruto (livro de factos) ou pode ajudá-lo a criar apresentações a partir dos conjuntos de dados disponíveis no relatório.

Perguntas frequentes

The Middle East and Africa Clinical Trial Supplies Market will be projected to grow at a CAGR of 7.0% during the forecast period of 2022 to 2029.
The Middle East and Africa Clinical Trial Supplies Market is projected at USD 62.01 million during the forecast period of 2022 to 2029.
The major players operating in the Middle East and Africa clinical trial supplies market are Movianto (U.S.), Sharp (U.S.),Thermo Fisher Scientific Inc.,(U.S.), Catalent, Inc (U.S.), PCI Pharma Services (U.S.), Almac Group (U.K.), PAREXEL International Corporation (U.S.), Bionical Ltd. (U.K.), Alium Medical Limited (U.K.), MYODERM (U.K.), Clinigen Group plc (U.K.), Ancillare, LP (U.S.), SIRO Clinpharm (India) CLINICAL SUPPLIES MANAGEMENT HOLDINGS, INC. (U.S.) Biocair (U.K.) and among others.
Rising Demand for Clinical Trial Worldwide, Increasing Incidence of Chronic Diseases and Government Funds in R&D Investments are the significant factors flourishing the growth of the Middle East and Africa Clinical Trial Supplies Market.